These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10568664)

  • 1. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone.
    Ogunyankin KO; Singh BN
    Am J Cardiol; 1999 Nov; 84(9A):76R-82R. PubMed ID: 10568664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
    Piccini JP; Schulte PJ; Pieper KS; Mehta RH; White HD; Van de Werf F; Ardissino D; Califf RM; Granger CB; Ohman EM; Alexander JH
    Crit Care Med; 2011 Jan; 39(1):78-83. PubMed ID: 20959785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
    Yap YG; Camm AJ
    Am J Cardiol; 1999 Nov; 84(9A):83R-89R. PubMed ID: 10568665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class III antiarrhythmic drugs.
    Singh BN; Ahmed R
    Curr Opin Cardiol; 1994 Jan; 9(1):12-22. PubMed ID: 8199363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha DB
    Am J Cardiol; 1999 Nov; 84(9A):46R-51R. PubMed ID: 10568659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
    Finance O; Manning A; Chatelain P
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):570-6. PubMed ID: 8569217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.
    Proclemer A; Facchin D; Vanuzzo D; Feruglio GA
    Cardiovasc Drugs Ther; 1993 Aug; 7(4):683-9. PubMed ID: 8241012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone: maximising survival benefit with empiric or guided therapy.
    Steinbeck G; Dorwarth U; Hoffmann E
    J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():51-5. PubMed ID: 10590489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction: What does the crystal ball tell you?
    Auer J; Lamm G
    Crit Care Med; 2011 Jan; 39(1):204-5. PubMed ID: 21178539
    [No Abstract]   [Full Text] [Related]  

  • 15. Overview of trends in the control of cardiac arrhythmia: past and future.
    Singh BN
    Am J Cardiol; 1999 Nov; 84(9A):3R-10R. PubMed ID: 10568654
    [No Abstract]   [Full Text] [Related]  

  • 16. Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials.
    Farré J; Romero J; Rubio JM; Ayala R; Castro-Dorticós J
    Am J Cardiol; 1999 Mar; 83(5B):55D-63D. PubMed ID: 10089841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study.
    Klingenheben T; Grönefeld G; Li YG; Hohnloser SH
    J Am Coll Cardiol; 2001 Dec; 38(7):2013-9. PubMed ID: 11738309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management.
    Anderson JL
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):880-6. PubMed ID: 8548109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.
    Van Herendael H; Dorian P
    Vasc Health Risk Manag; 2010 Aug; 6():465-72. PubMed ID: 20730062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of antiarrhythmic drug trials.
    Connolly SJ
    Am J Cardiol; 1999 Nov; 84(9A):90R-93R. PubMed ID: 10568666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.